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Abstract 
Background: Activated platelets shed microparticles (MPs) in vivo and certainly in vitro under storage. Like 
platelets, platelet-derived MPs contribute to hemostatic and inflammatory responses. We sought to determine the 
interactions between platelet MPs and peripheral B lymphocytes in the healthy blood circulation to propose a 
possible role for platelet MPs in the functioning of B cells.   
Materials and Methods: An enzyme-linked immunosorbent assay (ELISA) was established to determine the 
normal interactions between human peripheral blood B lymphocytes and platelet MPs. B cells were isolated and 
bound to the wells of microtiter plates using coated anti-CD19. Then the presence of attached MPs was surveyed. 
Also, platelet MPs were separated from human platelet concentrates and applied to confirm the new binding 
capacities of B cells for these microvesicles.  
Results: Platelet MPs were recognized in the wells of ELISA in which only B cells were isolated. So MPs were 
bound with peripheral blood B cells. Furthermore, using this method, the role of CD40/ CD40L interaction was 
displayed for the binding.  
Conclusion: It seemed that the binding of platelet MPs to B cells normally took place in vivo and a percent of B 
cells circulate in blood in connection with platelet MPs. 
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Platelets are enucleated cellular fragments 
produced by megakaryocytes and are best known for 
their role in hemostasis (1). These cellular elements 
participate in inflammation by releasing various 
proinflammatory substances that interact with 
circulating leukocytes and endothelial cells lining 
vessels (2, 3). However, recent studies indicate an 
additional role in modulating adaptive immune 
responses. In this regard, platelets have been shown 
to modulate dendritic cell activation (4-6), enhance 
T-cell responses (4, 7), induce B-cell production of 
IgG antibodies (4, 8), and enhance germinal center 
(GC) formation in cooperation with T cells (1, 9). 
Many reports show that CD40L is expressed on 
platelets, and soluble CD40L (sCD40L) is released 
from platelets after activation. The high concentrations 
of sCD40L in platelet preparations might explain the 
febrile or adverse responses associated with platelet 
transfusion. The CD40/CD40L interaction is important 
for many steps of B-cell differentiation (2, 10-12). The 
interaction of CD40 and CD40L (CD154) is critical 
for formation of germinal centers (GCs) (13-16). The 
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pivotal role of CD40-CD40L in T cell-dependent B 
cell responses was proven by the finding that patients 
suffering from the X-linked hyper-IgM syndrome 
(HIGM), were characterized by mutations in their 
CD40L gene (17, 18). 
MPs (MPs), microvesicles or ectosomes are 
shed from several cell types including leukocytes, 
erythrocytes, endothelial cells and various cancer 
cells (19). Existence of MPs was first noticed by 
Wolf in 1967 that described for the first time 
platelet’s membrane fragments originated from 
activated platelet called platelet dust (20). MPs 
expose phosphatidylserine and display surface 
plasma membrane markers from their parental cells 
(21, 22). MPs derived from platelets may transfer 
many platelet antigens to the surfaces of 
hematopoietic stem-progenitor cells (23). They 
contribute to haemostatic and inflammatory 
responses, vascular remodeling, angiogenesis, cell 
survival, and apoptosis (22, 24, 25). MPs are also 
present, and accumulate, in blood products such as 
erythrocyte and platelet concentrates during storage 
(26). It has long been thought that 70–90% of MPs in 
plasma are derived from activated platelets in 
comparison to other MP generating cells which 
contribute to the total pool. Typically, MPs range in 
size from 0.1 µm to 1 µm (19, 21, 27).  PMP surface 
is approximately 50- to 100-fold more procoagulant 
than the surface of activated platelets (28). 
We examined the capacity of platelet MPs for 
binding to human peripheral blood B cells and the 
presence of platelet MP/B cell aggregates in human 
healthy blood. Also, we designed an ELISA method 
to obtain different information about the platelet 
MP/B cell interactions. 
Methods 
Sample preparation. Informed consent was 
obtained from the blood candidates by Iranian Blood 
Transfusion Organization (IBTO). Five whole blood 
and five single donor platelet concentrates (PC, JMS 
Singapore Pte Ltd.) were prepared from IBTO (24 
hours after PC preparation and completion of the 
viral safety tests). 
B cells isolation from human whole blood 
using panning method (positive selection). Briefly, 
microtiter plates (Greiner bio-one, Frickenhausen, 
Germany) were coated with 100 μL of a 5 μg/ml 
solution of anti-CD19 (Abcam, UK) per well. The 
phosphate-buffered saline (PBS), pH 7.8 was used, 
and the plates were left 2 hours at 37ºC. Blocking of 
the plates was performed using a 2 % solution of BSA 
in PBS (3 h, RT), followed by incubation with 100 μL 
of the ficol-isolated buffy coats and incubation at 4ºC 
for overnight. After washing step, the adhered B cells 
were used to screen for the presence of platelet MPs. 
Isolation of platelet-derived MPs from 
platelet concentrate. For preparing platelet-derived 
MPs from platelet concentrates, platelets were 
transferred into 15 ml falcon tubes. The tubes were 
centrifuged at 150 g for 15 min to remove remaining 
white and red blood cells. The supernatant were 
separated and then depleted from platelets using two 
times centrifugation at 1200 g for 15 min. Finally MPs 
were isolated using centrifugation at 16000 g for 15 
min.  
Evaluation of the binding of B cells and 
platelet-derived MPs using ELISA method. 
Paraformaldehyde (0.5%) was used to fix absorbed B 
cells in the ELISA wells.  In the next step, 0.1 M 
glycine in phosphate buffer was employed to react 
with free aldehyde groups and prevent unspecific 
binding during ELISA procedure. Then after washing 
step, in screening for platelet MPs and their binding to 
B cells, biotin-conjugated anti-human gpIb (Gentaur 
Europe BVBA, Brussels, Belgium) was added. Again, 
45 minutes incubation at RT was chosen. Subsequent 
to routine washing step, addition of streptoavidin-HRP 
(Antigenix America, Huntington Station, NY, USA) 
was accomplished (Fig.1). Once more, 40 minutes 
incubation at RT was chosen. After washing step, the 
enzymatic activity was determined using tetramethyl–
benzidine (Usb, USA) as substrate. Notably, the wells 
devoid of the coated antigen or the specific antibody to 
gpIb were used as negative controls.  
Alternatively, isolated MPs were used to study 
the additional binding sites on B cells for MPs.  100 
μL of anti-CD40L (4 μg/ml, Abcam, UK) treated or 
untreated MPs were added to the wells containing B 
cells for 45 min/RT. The experiment was continued as 
mentioned above to complete ELISA protocol.  
Instead,  in an independent experiment, mouse 
IgG (1 µg/ml) was added to all wells of ELISA plate 
for 30 min before addition of anti-gpIbα for being 
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certain of the specificity of the binding of anti-human 
gpIb to MPs and to demonstrate that the binding 
was taken place via antigen binding site and not by 
FC receptors. 
B cells/ MPs Aggregates in the culture 
medium. Buffy coats were obtained from ficol-
treated human whole blood. B cells were isolated by 
negative selection method using anti-CD16 (Abcam, 
UK), anti-CD3 (Abcam, UK), anti-CD14 (Dako, 
Denmark), and Dynabeads® goat anti-mouse IgG 
(invitrogen Dynal AS, Oslo, Norway). The cells 
(106/ml) were co-cultured with platelet MPs (500 
μg/ml). After 7 days samples were taken and stained 
with hematoxylin-eosin method. 
Results 
Evaluation of B cell binding to platelet MPs 
using ELISA method. As it could be seen in Table 
1, the mean OD450 for uncoated wells was 
determined 0.19±0.014 whereas it was determined 
for B cells (alone); 0.508±0.001. This absorbance 
could demonstrate the presence of MPs in the wells 
of ELISA plate in attachment with B cells (Fig.1). 
Treatment of B cells with MPs changed the OD450 
to 1.273±0.165. So the increasing of OD450 could be 
attributed to binding of MPs to non-saturated sites of 
B cells for MPs. Additionally, previous treatment of 
MPs with anti-CD40L and addition to B cells 
decreased OD450 to 0.805±0.052. This result 
implied that the CD40-CD40L molecules have a role 
in the interaction of B cells and platelet MPs so 
application of antibodies against CD40L could affect 
the interaction (Table 1).  
Alternatively, in the ELISA protocol, we also 
used mouse IgG before addition of anti-gpIb to be 
certain of the specific binding of anti-gpIb antibody 
to gpIb and not to FC receptors. As it could be seen 
in Table 2, the mean OD450 for B cells alone was 
0.552±0.12. Whereas treatment of B cells with MPs 
changed the OD450 to 1.522±0.02. So again, the 
increasing of OD450 could be also attributed to the 
additional binding capacity of B cells for MPs. It is 
worth mentioning that previous treatment of MPs with 
anti-CD40L decreased OD450 to 0.867±0.02. This 
result showed that the CD40 and CD40L molecules 
have a role in the interaction of B cells and platelet 
MPs so application of anti-CD40L could affect the 
interaction (Table 2).  
B cells/ MPs Aggregate in the culture 
medium. As it could be seen in the simultaneous 
culture of human B cells and platelet-derived 
microparticles, aggregates were formed between them 
(Fig.2). It seemed that MPs could bridge between the 
Table 1: OD450 (mean±SD) obtained in ELISA 
method for the screening of platelet MPs attached to B 
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Table 2: OD450 (mean±SD) obtained in ELISA 
method for the screening of platelet MPs in attachment 
with B cells.  Mouse IgG was used before addition of 
anti-gpIbα as mentioned under Materials and Methods. 
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Platelet MPs comprised most of the MPs in 
human circulation. The result of this study showed 
that platelet MPs like platelets could bind to human 
B cells. Additionally, a proportion of B cells adhered 
to MPs normally and created aggregates that 
circulate in the healthy blood.  
Cognasse in 2007 showed that in co-culture, 
platelets and B lymphocytes were bound and 
mutually activated, as demonstrated by the increased 
expression of platelet CD62P and B-cell CD86. 
Platelet/B-cell interactions were accompanied by 
changes in membrane expression of CD40 and 
CD40L by both platelets and B lymphocytes (2). In 
accordance, our study demonstrated the role of 
CD40L for the binding of platelet MPs to B cells in 
vitro.  
In 2003, Héloire and coworkers reported the 
presence of aggregates of endothelial MPs and 
platelets in the healthy human blood. In this study, it 
showed that activated endothelial cells MPs can 
interact with platelets and form aggregates in vitro 
and in vivo (29). We obtained similar results for 
platelet MPs and B cells.  
Conclusion 
Our study introduced a novel application of 
ELISA method for studying the interactions between 
MPs of different sources and the cells. Additionally, 
new binding capabilities could also be studied using 
this method with addition of the MPs to the interest  
target cells in the wells of ELISA plate. Alternatively, 
the molecules that were engaged in the interaction 
could be investigated and recognized using this 
technique as it was described previously. 
Although there were some studies about 
application of platelet MPs in the mouse models to 
show their effects on the production of antibodies from 
B cells, we didn't find any report about the existence 
of aggregates of B cells and platelet MPs in the human 
peripheral blood. This finding may imply a role for 
platelet MPs in the regulation of B cells function in 
vivo. Further studies could be carried out to reveal the 
potential role of platelets MPs in the adaptive immune 
response. 
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Figure 1. A schematic representation for different 
stages in an established ELISA method 
 
 
Figure 2. Microscopic examination of the interaction of  
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